Influenza drug to undergo “fast track” assessment by NICEBMJ 1999; 319 doi: https://doi.org/10.1136/bmj.319.7207.400 (Published 14 August 1999) Cite this as: BMJ 1999;319:400
- Judy Jones
The influenza drug zanamivir (Relenza) will undergo “fast track” appraisal by the new National Institute for Clinical Excellence (NICE), which will recommend which treatments should be available on the NHS in England and Wales. Zanamivir is said to moderate the symptoms of flu and shorten bouts of the illness.
Professor Sir Michael Rawlins, the institute's chairman, said last week that he hopes to publish recommendations on the use of the drug this autumn. Thereafter, the …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial